{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "1260196220", "close" : "1260219620", "flags" : {}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}
marketwire

Transaction in Own Shares

  • Press Release
  • Source: Novo Nordisk A/S
  • On 9:58 am EDT, Monday October 26, 2009

BAGSVAERD, DENMARK--(Marketwire - 10/26/09) - Novo Nordisk A/S - Share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.

Since the announcement as of 19 October 2009, the following transactions have been made under the programme:

�
                  Number of    Average     Transaction value,
                   shares   purchase price        DKK
Accumulated, last
announcement      3,878,000                     1,236,185,523
19 October 2009      61,000       325.0630         19,828,843
20 October 2009      75,000       326.1799         24,463,493
21 October 2009      75,000       324.5900         24,344,250
22 October 2009      72,600       322.5850         23,419,671
23 October 2009      60,450       322.4490         19,492,042
Accumulated under
the programme     4,222,050                     1,347,733,822

With the transactions stated above, Novo Nordisk owns a total of 29,058,858 treasury shares, corresponding to 4.7% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Company Announcement no 62 / 2009

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright � Hugin AS 2009. All rights reserved.

Contact:



Further information:
Media:
Outside North America:
Elin K Hansen
Tel: (+45) 4442 3450
Email Contact
In North America:
Sean Clements
Tel: (+1) 609 514 8316
Email Contact
Investors:
Outside North America:
Mads Veggerby Lausten
Tel: (+45) 4443 7919
Email Contact
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
Email Contact
In North America:
Hans Rommer
Tel: (+1) 609 919 7937
Email Contact

Sponsored Links

Copyright © 2009 Marketwire. All rights reserved. All the news releases provided by Marketwire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.